Ramucirumab Plus Docetaxel for Patients with Non-small cell Lung Cancer with Brain Metastases: A Multicenter, Open-Label Single-Arm Phase II Trial.

Keiko Tanimura,Junji Uchino,Hideharu Kimura,Osamu Hiranuma,Yusuke Chihara,Shigeru Tanzawa,Chieko Takumi,Toshiyuki Kita,Koji Inoue,Koichi Minato,Shinnosuke Takemoto,Akira Nakao,Kenichi Yoshimura,Koichi Takayama

The oncologist（2023）

引用 0|浏览4

暂无评分

摘要

No clinical concerns were identified with DOC/RAM for NSCLC with brain metastases in this study. Further investigation with a larger sample size is needed to determine the tolerability and safety of these populations (Trial Identifiers: University Hospital Medical Information Network in Japan [UMIN000024551] and Japan Registry of Clinical Trials [jRCTs071180048]).

查看译文

关键词

VEGF,brain metastases,docetaxel plus ramucirumab,non-small cell lung cancer,sVEGFR-2

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要